Daratumumab + Lenalidomide for Multiple Myeloma
(AURIGA Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing whether adding daratumumab to lenalidomide is more effective than using lenalidomide alone for patients with newly diagnosed multiple myeloma. These patients still have detectable cancer cells after initial treatments. Daratumumab helps the immune system find and kill cancer cells, while lenalidomide boosts the immune system and stops cancer growth.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is the combination of Daratumumab and Lenalidomide safe for treating multiple myeloma?
The combination of Daratumumab and Lenalidomide, often used with Dexamethasone, has been shown to be generally safe for treating multiple myeloma, with common side effects including low blood cell counts, nerve damage, and infections. No new safety concerns have been identified in recent studies.12345
What makes the drug combination of Daratumumab and Lenalidomide unique for treating multiple myeloma?
This drug combination is unique because it combines Daratumumab, a monoclonal antibody that targets and kills myeloma cells, with Lenalidomide, an immunomodulatory drug, enhancing the immune system's ability to fight the cancer. This combination has shown to improve progression-free survival and overall response rates in patients with multiple myeloma compared to standard treatments.13678
What data supports the effectiveness of the drug combination Daratumumab and Lenalidomide for treating multiple myeloma?
Who Is on the Research Team?
Janssen Research & Development, LLC Clinical Trial
Principal Investigator
Janssen Research & Development, LLC
Are You a Good Fit for This Trial?
This trial is for individuals with newly diagnosed multiple myeloma who have had at least 4 cycles of induction therapy, a stem cell transplant within the last year, and are still showing minimal residual disease. They should be in relatively good health (ECOG score 0-2) and not have been treated with Daratumumab or similar drugs before.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive daratumumab plus lenalidomide or lenalidomide alone as maintenance therapy for a maximum of 36 cycles
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Daratumumab
- Lenalidomide
Lenalidomide is already approved in European Union, United States for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Janssen Research & Development, LLC
Lead Sponsor
Joaquin Duato
Janssen Research & Development, LLC
Chief Executive Officer since 2022
MBA from ESADE, Master of International Management from Thunderbird School of Global Management
Dr. Jijo James, MD
Janssen Research & Development, LLC
Chief Medical Officer since 2014
MD from St. Johns Medical College, MPH from Columbia University